Tests furosemide given into the abdomen for fluid control in peritoneal dialysis
Compares abdominal and oral furosemide for fluid balance in stable adults on peritoneal dialysis.
Key facts
- Who runs it
- Fundacion Para El Fomento De La Investigacion Sanitaria Y Biomedica De La Comunitat Valenciana
- Where
- Valencia, SpainSee the site
- Trial code
- Registry title
- Efficacy and safety trial of intraperitoneal furosemide in patients on peritoneal dialysis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 37 people, planned
- Started
- 13 Jun 2025
- Expected to end
- 31 Mar 2027
- Type of study
- Interventional
- Record updated
- 17 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults on peritoneal dialysis who take a steady, higher dose of oral furosemide. It compares furosemide given into the abdomen with furosemide taken by mouth.
- Age
- Over 18 years
- Sex
- All sexes can join.
- Disease stage
- Clinically stable on peritoneal dialysis (PD), with a PD catheter that works well and urine output of more than 500 ml per day.
- Earlier treatment
- Must have taken a stable oral furosemide dose of 120 mg or more per day during the previous fifteen days. Must have had a peritoneal equilibrium test in the previous three months.
Main reasons for not taking part
- Allergy to furosemide
- Patient or caregiver cannot give the treatment into the abdomen at home
- Need to change the other oral water tablets (diuretics) when joining or during the trial
This trial only enrols participants on dialysis. The registry sentence this rests on: Clinically stable patients in PD technique
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Patients on treatment with a daily dose equal to or higher than 120 mg of stable oral furosemide during previous fifteen days
- Patients over 18 years of age
- Clinically stable patients in PD technique
- Patients with a normofunctioning PD catheter
- Patients with residual diuresis greater than 500ml per day
- Patients who have undergone a peritoneal equilibrium test in the previous three months
- Patients who wish to participate and who sign the informed consent form
Who cannot take part
- Inability of the patient or caregiver to administer intraperitoneal therapy at home
- Allergy to furosemide
- Need to modify the rest of the oral diuretic treatment at the time of inclusion in the study and during follow-up
Where in Spain
- Hospital Universitario Dr. Peset AleixandreValencia, SpainTaking people
About the trial
What the trial wants to find out
To study the clinical response to furosemide administered intraperitoneally compared to orally on the hydration status of stable patients in a PD unit.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Efficacy and safety trial of intraperitoneal furosemide in patients on peritoneal dialysis
- Plain-language title
- Tests furosemide given into the abdomen for fluid control in peritoneal dialysisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 17 June 2026